AbbVie Inc. (ABBV) News and Biopharmaceutical & Healthcare Updates
AbbVie Inc., headquartered in North Chicago, Illinois, develops advanced therapies in immunology, oncology, neuroscience, eye care, and medical aesthetics. Its key products include Humira, Skyrizi, and Botox (via Allergan). AbbVie focuses on research-driven innovation and expanding patient access to next-generation treatments worldwide.
243.14
8.25
3.51 %
At close
06/25
USD
Daily range
233.66
244.50
244.50
Weekly range
221.94
237.36
237.36
AbbVie stock climbs after Upadacitinib approval filings with FDA and EMA
AbbVie (ABBV) stock is trading at $242.77, marking an increase of 3.35% for the day. The price is currently above its key moving averages, reflecting strong momentum ...
AbbVie shares jump as stock buying pressure builds
AbbVie Inc. (ABBV) climbed 3.33% after announcing a $10.9 billion acquisition agreement for Apogee Therapeutics, expanding its immunology pipeline and reinforcing buying interest. The strength of ...
AbbVie stock trades up to $234.93 as AbbVie recaps EHA Hematology Congress events
AbbVie provided an inside look at highlights from the EHA Hematology Congress. The company connected with colleagues and global hematology experts to shape the future of blood cancer care.AbbVie ...
AbbVie stock trades up to $234.93 as AbbVie recaps EHA Hematology Congress events
AbbVie provided an inside look at highlights from the EHA Hematology Congress. The company connected with colleagues and global hematology experts to shape the future of blood cancer care.AbbVie ...
AbbVie stock rallies with price holding above key moving averages: weekly outlook
AbbVie Inc. (ABBV) finished the week at $232.58, posting a strong gain of $15.95 or 7.22% over the last 7 trading days. The asset is trading well above its weekly MA-20 ...
Apogee Therapeutics acquisition drives AbbVie stock up 4.48%
AbbVie Inc. (ABBV) stock is trading at $226.33, up 4.48% on the day. The price is positioned above its key moving averages, reflecting a strong positive move within the ...
What is behind AbbVie stock's recent drop in value today
AbbVie Inc. (ABBV) is trading near $216.02, down 2.36% for the day. The stock has slipped below its 20-day moving average of $219.80 but remains above the 50-day average at $211.67, reflecting ...
AbbVie stock slides to lower edge of recent range as buyers show dominance: weekly outlook
AbbVie Inc. (ABBV) is currently trading at $222.47, down $5.26 or 2.31% over the past week. The stock remains above both its weekly MA-20 ($216.49) and MA-50 ($216.61), ...
ABBV shares consolidate near $225 with MACD signaling caution at recent highs: weekly forecast
AbbVie Inc. (ABBV) closed the week at $225.45, recording a decline of $1.78 or 0.78% from the prior week and remaining in the upper range of its recent weekly trading ...
AbbVie unveils blood cancer advancements as stock holds near highs despite mild pullback
AbbVie will be showcasing its clinical advancements across multiple blood cancers at EHA Hematology.AbbVie will also be connecting with the global community at the event. Details are being ...
European approval for Aquipta therapy lifts AbbVie stock higher
AbbVie Inc. (ABBV) stock is trading at $224.00 after rising 3.16% on the day, with the price positioned above its key short-, medium-, and long-term moving averages. ...
AbbVie stock edges higher to $217.88 after EULAR 2026 research announcement, abbvie posts
AbbVie reported that it will have 26 accepted abstracts across five rheumatic diseases at EULAR 2026.An animation showed diverse profile illustrations transitioning to on-screen text about the ...
Selling pressure pushes AbbVie stock lower in today's trading
AbbVie Inc. (ABBV) is trading at $211.98 after a $5.60 decline, down 2.57% on the day. The stock sits just above its 20-day and 50-day moving averages, but remains below the 200-day, signaling ...
ABBV stock shows mixed momentum as current volatility rises to 3.90%: weekly analysis
AbbVie Inc. (ABBV) is currently trading at $214.11, sitting slightly below both the weekly MA-20 ($215.42) and MA-50 ($214.87), but well above the MA-200 ($177.44). Over ...
AbbVie stock moves up amid positive EMA recommendations for key drugs: weekly review
AbbVie Inc. (ABBV) is currently trading at $215.70 after gaining $5.31 (2.52%) over the past week, closing in the upper part of its recent weekly range. The asset sits ...
ABBV stock holds steady below resistance at $213.82 as technical pressure persists: weekly outlook
AbbVie Inc. (ABBV) closed the week at $209.54, declining $0.85, or 0.40%, from the previous week. The price remains below both the Weekly MA-20 ($216.22) and MA-50 ...
AbbVie shares consolidate as technicals point to continued selling pressure: weekly report
AbbVie Inc. (ABBV) is currently trading at $204.68, standing below the weekly MA-20 ($217.20) and MA-50 ($213.33), while maintaining a strong buffer above the MA-200 ...
ABBV shares surge with Skyrizi and Rinvoq sales offsetting Humira decline: weekly forecast
AbbVie Inc. (ABBV) finished the week at $212.96, registering a $14.25 (6.97%) gain and closing at the top of its weekly range. The stock now trades just above its weekly ...
AbbVie stock moves down with RSI signaling oversold conditions near $204: weekly analysis
AbbVie Inc. (ABBV) is currently trading at $204.72, reflecting a weekly decline of $3.65 or 1.75%. The stock remains below its weekly MA-20 at $219.62 and MA-50 at ...
ABBV stock shows mixed momentum on neutral MACD reading: weekly review
AbbVie Inc. (ABBV) is currently trading at $208.51, reflecting a nearly flat performance over the past week — a $0.46 rise that leaves the asset essentially unchanged ...
What is behind AbbVie stock's recent drop in value today
AbbVie Inc. (ABBV) is currently trading at $203.48, down 2.20% for the day. The stock remains below its 20-day, 50-day, and 200-day moving averages ($210.89, $220.48, and $216.76, respectively), ...
